HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

CVRX

CVRx, Inc. (NASDAQ)

Healthcare — Medical Devices

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

None 6 analysts
$5.50
+$0.36 (+7.00%)
Target: $11.17 (103.0%)
Sign in to add CVRX to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$145.95M
P/E Ratio (TTM)-
Forward P/E-2.90
EPS (TTM)$-2.01
Dividend Yield-
Profit Margin-89.14%
Revenue Growth19.60%
ROE-106.96%
Debt/Equity204.04
Recommendation None
Analyst Target$11.17
Analysts6
Indexes NASDAQ

Technical Indicators

RSI (14)61.8
Beta0.77
SMA 20-
SMA 40-
52-Week High$11.30
52-Week Low$4.37
50-Day Avg$6.05
200-Day Avg$7.62
Avg Volume327.6K
Volume332.2K

Performance Analysis

NEUTRAL

CVRX presents a mixed picture with both positive and negative indicators.

~ Trading at 16% of its 52-week range.
+ RSI at 61.8 shows positive momentum.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 19.6% year-over-year.
- Operating at a loss with -89.1% margin.
~ Wall Street consensus is "none" from 6 analysts.
+ Average analyst target of $11.17 implies 103.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:05 UTC

Back to Screener Export Report